Changzhou Fangyuan Pharma is ready for clinical trials in China to test its nearly decade-long work on a tricky-to-make semisynthetic, methicillin-resistant…

Hanmi Pharmaceutical eyes branded drugs, fast-paced R&D and investment in China to get growth on track.

India's drug regulatory system--currently split between federal goals and state implementation--needs an overhaul that puts one superagency at the top.

As many as 500 drug manufacturing plants in India will be inspected head-to-toe in a phased effort to ensure good manufacturing practice compliance and…

Cipla will build a biosimilar manufacturing plant in South Africa for SAR1.3 billion ($89 million)--marking the first such type of unit outside of India.

Nippon Kayaku said a Phase III study of a breast cancer candidate in-licensed from NanoCarrier--NK105--missed its primary endpoint.

The U.N.'s Medicines Patent Pool has signed a variety of sublicense agreements covering generics of four HIV antiretroviral treatments and hepatitis C…

Breakthrough hepatitis C therapy Epclusa (sofosbuvir and velpatasvir) from Gilead Sciences has been licensed to 11 Indian companies following its recent U.S.…

Taiwan Liposome President George Yeh discussed the company's unique efforts in drug delivery, clinical trials and lab work and position as a pioneer in…